Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications

BACKGROUND: New therapies are urgently needed in melanoma particularly in late-stage patients not responsive to immunotherapies and kinase inhibitors. METHODS: Drug screening, IC50 determinations as well as synergy assays were detected by the MTT assay. Apoptosis using Annexin V and 7AAD staining wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wei, Stachura, Paweł, Xu, Haifeng C., Umesh Ganesh, Nikkitha, Cox, Fiona, Wang, Ruifeng, Lang, Karl S., Gopalakrishnan, Jay, Häussinger, Dieter, Homey, Bernhard, Lang, Philipp A., Pandyra, Aleksandra A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035645/
https://www.ncbi.nlm.nih.gov/pubmed/32085796
http://dx.doi.org/10.1186/s13046-020-1539-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035645/
https://www.ncbi.nlm.nih.gov/pubmed/32085796
http://dx.doi.org/10.1186/s13046-020-1539-7

Ejemplares similares